Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Galmed Pharmaceuticals Ltd

Current price
0.37 USD -0.029 USD (-7.23%)
Last closed 0.39 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 328 138 USD
Yield for 12 month -91.37 %
21.11.2021 - 28.11.2021

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Tiomkin Street, Tel Aviv, Israel, 6578317

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-31 000 USD

Last Year

-35 000 USD

Current Quarter

-6 000 USD

Last Quarter

Key Figures GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -7 461 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -28.22 %
PEG Ratio
Return On Equity TTM -50.63 %
Wall Street Target Price 1 USD
Revenue TTM
Book Value 2.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.5 USD
Diluted Eps TTM -2.5 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GLMD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 15.05.2023
Dividend Date

Stock Valuation GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 1.3509
Price Book MRQ 0.1817

Financials GLMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GLMD

For 52 weeks

0.26 USD 5 USD
50 Day MA 0.37 USD
Shares Short Prior Month 83 762
200 Day MA 0.45 USD
Short Ratio 1.28
Shares Short 72 782
Short Percent 1.26 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics